Maximova, N.; Nisticò, D.; Riccio, G.; Maestro, A.; Barbi, E.; Faganel Kotnik, B.; Marcuzzi, A.; Rimondi, E.; Di Paolo, A.
Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study. Cancers 2023, 15, 3605.
https://doi.org/10.3390/cancers15143605
AMA Style
Maximova N, Nisticò D, Riccio G, Maestro A, Barbi E, Faganel Kotnik B, Marcuzzi A, Rimondi E, Di Paolo A.
Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study. Cancers. 2023; 15(14):3605.
https://doi.org/10.3390/cancers15143605
Chicago/Turabian Style
Maximova, Natalia, Daniela Nisticò, Guglielmo Riccio, Alessandra Maestro, Egidio Barbi, Barbara Faganel Kotnik, Annalisa Marcuzzi, Erika Rimondi, and Antonello Di Paolo.
2023. "Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study" Cancers 15, no. 14: 3605.
https://doi.org/10.3390/cancers15143605
APA Style
Maximova, N., Nisticò, D., Riccio, G., Maestro, A., Barbi, E., Faganel Kotnik, B., Marcuzzi, A., Rimondi, E., & Di Paolo, A.
(2023). Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children: A Prospective, Single-Center Study. Cancers, 15(14), 3605.
https://doi.org/10.3390/cancers15143605
